These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22332769)

  • 1. Sorafenib rechalenge in metastatic renal cell carcinoma.
    Porta C; Paglino C; Imarisio I
    BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
    Raspollini MR
    Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy for metastatic RCC--questions remain.
    Breau RH; Leibovich BC
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
    Tomita Y
    Int J Urol; 2010 Sep; 17(9):815-6. PubMed ID: 20727052
    [No Abstract]   [Full Text] [Related]  

  • 5. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S; Hertle L; Nitschmann S
    Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
    Wu Y; Zhao Y
    Int J Urol; 2011 Jun; 18(6):430-1. PubMed ID: 21599760
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y
    Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
    Lekili M; Muezzinoglu T; Nese N; Temeltas G
    J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 10. A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from renal cell carcinoma 17 years from diagnosis.
    Benincasa E; Conti A; Bossone G; Gallà DA; Gianciotta A; Zuccaro SM; Madaio R
    Tumori; 2009; 95(3):403. PubMed ID: 19688987
    [No Abstract]   [Full Text] [Related]  

  • 11. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE; Rini BI; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
    Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
    [No Abstract]   [Full Text] [Related]  

  • 14. Tilting the AXIS towards therapeutic limits in renal cancer.
    Bex A; Haanen J
    Lancet; 2011 Dec; 378(9807):1898-900. PubMed ID: 22056245
    [No Abstract]   [Full Text] [Related]  

  • 15. Health policy: The UK 'postcode lottery' in renal cell carcinoma.
    Larkin J; Gore M
    Nat Rev Urol; 2009 Dec; 6(12):636-8. PubMed ID: 19956190
    [No Abstract]   [Full Text] [Related]  

  • 16. [Renal cell carcinoma].
    Oya M
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):29-31. PubMed ID: 20140991
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial comment.
    Rini BI; Shah SN
    Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment.
    Vaishampayan U
    Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
    Valcamonico F; Ferrari V; Amoroso V; Rangoni G; Simoncini E; Marpicati P; Vassalli L; Grisanti S; Marini G
    J Neurooncol; 2009 Jan; 91(1):47-50. PubMed ID: 18712279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.